Softwr

Healthcare · head to head

NextGen Enterprise EHR vs Paige

NextGen Enterprise EHR logo

NextGen Enterprise EHR

Healthcare

Enterprise-grade EHR and RCM for large healthcare organizations

From
On request
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: NextGen Enterprise EHR no pricing published on website; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: NextGen Enterprise EHR covers Electronic Health Records, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which NextGen Enterprise EHR and Paige actually diverge.

Attributes where NextGen Enterprise EHR and Paige differ
AttributeNextGen Enterprise EHRPaige
PlatformsWeb, DesktopWeb, Cloud, On-premise
Founded1997Unknown

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in NextGen Enterprise EHR

  • Electronic Health Records
  • Clinical Documentation
  • Revenue Cycle Management
  • Patient Management
  • Analytics
  • Interoperability
  • Reporting
  • HL7

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

NextGen Enterprise EHR

  • Patient Carenot Paige
  • Medical Recordsnot Paige
  • Practice Managementnot Paige
  • Telehealthnot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot NextGen Enterprise EHR
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot NextGen Enterprise EHR
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot NextGen Enterprise EHR
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot NextGen Enterprise EHR

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

NextGen Enterprise EHR

  • No pricing published on website

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

NextGen Enterprise EHR

On request

No published plan breakdown. See the NextGen Enterprise EHR review.

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose NextGen Enterprise EHR if

  • You need electronic health records.
  • You work on Web, Desktop.
  • You also want clinical documentation.
NextGen Enterprise EHR review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is NextGen Enterprise EHR or Paige better?
Neither clearly leads. NextGen Enterprise EHR starts at On request and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, NextGen Enterprise EHR or Paige?
NextGen Enterprise EHR starts at On request and Paige at On request.
Does NextGen Enterprise EHR or Paige run on more platforms?
NextGen Enterprise EHR runs on Web, Desktop. Paige runs on Web, Cloud, On-premise.
What is NextGen Enterprise EHR best used for?
NextGen Enterprise EHR is most often used for patient care, medical records, practice management, telehealth. Of those, patient care and medical records are not what Paige is typically brought in for.
What can NextGen Enterprise EHR do that Paige cannot?
NextGen Enterprise EHR covers Electronic Health Records, Clinical Documentation, Revenue Cycle Management, Patient Management. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

NextGen Enterprise EHR: What is NextGen Enterprise EHR pricing?

NextGen Healthcare does not publish pricing for its Enterprise solutions on their website. The company uses a consultative sales model where pricing is determined after understanding specific practice requirements and needed features.

Source
Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on NextGen Enterprise EHR

More on Paige

Keep looking

Other head to heads